Genentech

American biotechnology corporation

HIRING · 7 OPEN AI

About

Who We Are
Genentech (GNE), a member of the Roche group and founder of the biotechnology industry, is dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. To solve the world's most complex health challenges, we ask bigger questions that challenge our industry and the boundaries of science to transform society. Our transformational discoveries include the first targeted antibody for cancer and the first medicine...

Genentech

About

Updates & Highlights

Genentech, Novartis Accused of Drug Kickback Schemes in Lawsuit

FDA accepts Genentech filing for Lunsumio-Polivy combination

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

Recent Openings

All Jobs

Culture & Mission

Benefits & Perks

Equity/Stock Options

Health Insurance

Remote Work

Learning Budget

Generous PTO

Competitive Salary

Tech Stack

Core Values

Innovation

Collaboration

Excellence

Impact

Office Locations

Team

Are you on the team at Genentech?

News & Press

Genentech, Novartis Accused of Drug Kickback Schemes in Lawsuit

FDA accepts Genentech filing for Lunsumio-Polivy combination

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

Ex-Genentech exec moves Boulder biotech to Bay Area with $400 million in the bank

Former Genentech exec moves company to Bay Area from Colorado with $400 million in the bank

Genentech Gains FDA Priority Review for Oral SERD in Early Breast Cancer

Layoff Tracker: Genentech R&D cuts include longtime top exec

Lilly, Biogen, Eisai and Genentech sponsor new ‘Let’s Talk Alzheimer’s’ podcast

Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax

FDA accepts Genentech filing for Tecentriq in colon cancer By Investing.com

Genentech layoffs include elimination of infectious disease department

Genentech R&D layoffs hit top exec who’s been with the biotech nearly 30 years

Genentech executes another round of layoffs, with 3 VPs axed

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Genentech and Novartis dish up food allergy microdrama series

Exclusive: Genentech lays off top scientist Vishva Dixit, closes infectious disease research unit in restructuring

Statement from San Mateo County Assessor, Mark Church, Regarding Recent Mischaracterizations of the Genentech Property Tax Settlement

Nurix Therapeutics, Inc., F. Hoffmann-La Roche Ltd., and Genentech, Inc. Enter Global License and Collaboration Agreement to Co-Develop and Commercialize Bexobrutideg

FDA Approves Genentech’s Tecentriq for ctDNA-Guided Adjuvant Bladder Cancer Treatment

How Genentech uses Meridian for media measurement - Think with Google